Finance

Beta
Lists
HAPV3:BCBA
Hapvida Par e Invest Cedar
ARS 3,347.50
-8.66%
(-317.50) 1D
Jun 3, 5:00:00 PM GMT-3  ·   ARS
All symbols
SymbolPriceChange% Change
Generating top insights for HAPV3...
Open
ARS 3,562.50
High
ARS 3,582.50
Low
ARS 3,330.00
Mkt. cap
5.62B
Avg. vol.
9.40K
Volume
2.81K
52-wk high
ARS 11,800.00
52-wk low
ARS 550.00
Shares outstanding
502.63M
No. of employees
66K
Open
ARS 3,562.50
High
ARS 3,582.50
Low
ARS 3,330.00
Mkt. cap
5.62B
Avg. vol.
9.40K
Volume
2.81K
52-wk high
ARS 11,800.00
52-wk low
ARS 550.00
Shares outstanding
502.63M
No. of employees
66K
News stories
From sources across the web
About Hapvida Par e Invest Cedar
CEO-
Employees66K
Founded1979
Headquarters-
SectorHealth care provider
Previous reportsAll values in BRL
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in BRL
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
7.67B
7.92B
7.89B
8.08B
Cost of goods sold
-
6.97B
7.06B
6.85B
Cost of revenue
-
6.97B
7.06B
6.85B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
515.36M
548.28M
719.51M
Operating expense
-
557.73M
537.22M
694.61M
Total operating expenses
-
7.52B
7.59B
7.54B
Operating income
-
393.24M
301.80M
534.30M
Other non operating income
-
59.16M
-29.66M
-165.77M
EBT including unusual items
-
32.92M
-131.39M
76.91M
EBT excluding unusual items
-
75.01M
-118.79M
76.91M
Income tax expense
-
-54.19M
-47.73M
177.61M
Effective tax rate
-
-164.65%
36.33%
230.93%
Other operating expenses
-
42.37M
-11.06M
-24.90M
Net income
-
87.13M
-83.51M
-100.98M
Net profit margin
-
1.10%
-1.06%
-1.25%
Earnings per share
0.30
-
-
-
Interest and investment income
-
328.15M
280.25M
242.35M
Interest expense
-
-712.50M
-662.93M
-546.18M
Net interest expenses
-
-384.34M
-382.68M
-303.84M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
686.49M
489.60M
722.57M
Gain or loss from assets sale
-
74.45M
-49.92M
46.50M
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more